1. Home
  2. NLSP vs IPDN Comparison

NLSP vs IPDN Comparison

Compare NLSP & IPDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLSP
  • IPDN
  • Stock Information
  • Founded
  • NLSP 2015
  • IPDN 2003
  • Country
  • NLSP Switzerland
  • IPDN United States
  • Employees
  • NLSP N/A
  • IPDN N/A
  • Industry
  • NLSP Biotechnology: Pharmaceutical Preparations
  • IPDN EDP Services
  • Sector
  • NLSP Health Care
  • IPDN Technology
  • Exchange
  • NLSP Nasdaq
  • IPDN Nasdaq
  • Market Cap
  • NLSP 12.4M
  • IPDN 4.3M
  • IPO Year
  • NLSP 2021
  • IPDN 2013
  • Fundamental
  • Price
  • NLSP $2.10
  • IPDN $2.18
  • Analyst Decision
  • NLSP
  • IPDN
  • Analyst Count
  • NLSP 0
  • IPDN 0
  • Target Price
  • NLSP N/A
  • IPDN N/A
  • AVG Volume (30 Days)
  • NLSP 275.3K
  • IPDN 2.9M
  • Earning Date
  • NLSP 07-22-2025
  • IPDN 08-12-2025
  • Dividend Yield
  • NLSP N/A
  • IPDN N/A
  • EPS Growth
  • NLSP N/A
  • IPDN N/A
  • EPS
  • NLSP N/A
  • IPDN N/A
  • Revenue
  • NLSP N/A
  • IPDN $6,508,349.00
  • Revenue This Year
  • NLSP N/A
  • IPDN N/A
  • Revenue Next Year
  • NLSP N/A
  • IPDN N/A
  • P/E Ratio
  • NLSP N/A
  • IPDN N/A
  • Revenue Growth
  • NLSP N/A
  • IPDN N/A
  • 52 Week Low
  • NLSP $1.30
  • IPDN $0.97
  • 52 Week High
  • NLSP $15.59
  • IPDN $11.20
  • Technical
  • Relative Strength Index (RSI)
  • NLSP 46.61
  • IPDN 58.07
  • Support Level
  • NLSP $2.20
  • IPDN $2.10
  • Resistance Level
  • NLSP $3.08
  • IPDN $3.30
  • Average True Range (ATR)
  • NLSP 0.25
  • IPDN 0.45
  • MACD
  • NLSP -0.06
  • IPDN 0.04
  • Stochastic Oscillator
  • NLSP 8.40
  • IPDN 30.56

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

About IPDN Professional Diversity Network Inc.

Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.

Share on Social Networks: